Allergy Shots — How Do They Work? The 5-Step Immune Retraining Process

Allergy shots work through five sequential immune changes. First, allergen extract is injected subcutaneously, where dermal dendritic cells capture the allergen proteins. Second, dendritic cells carry allergen to regional lymph nodes and present it to T cells in a tolerogenic context. Third, T cells differentiate into regulatory T cells (Tregs) that produce IL-10, specifically suppressing the allergen-driven Th2 inflammatory response. Fourth, B cells class-switch from IgE to IgG4 production — IgG4 blocking antibodies rise 10- to 100-fold and intercept allergen before it can trigger mast cells. Fifth, mast cells and basophils in allergic tissues progressively desensitize, requiring far higher allergen doses to release histamine than before treatment. Clinical improvement follows once sufficient IgG4 and Treg activity accumulates, typically within 3 to 6 months of reaching maintenance dose.

Allergy shots take time because the immune retraining process is gradual and cumulative — not a single dose effect. Treg cells need time to expand and establish allergen-specific suppression. IgG4 blocking antibodies require 1 to 3 months to begin measurable rise and 1 to 3 years to reach their peak protective level of 10- to 100-fold above baseline. Mast cell desensitization in allergic tissues is a slow progressive process that unfolds over months of sustained high-dose allergen exposure. The 3-year minimum treatment requirement is not arbitrary — it reflects the time biology needs to establish durable immune tolerance rather than temporary suppression. Incomplete treatment is the most common reason for both slow initial response and post-treatment relapse.

Local reactions at the injection site — redness, swelling, and itching — occur in 26 to 86% of allergy shot patients and are considered a normal part of treatment, according to Tankersley et al. (JACI 2000). These reactions typically peak within 30 minutes to a few hours and resolve within 24 hours. They reflect the local immune activation occurring at the injection site as dendritic cells capture allergen. Importantly, individual local reactions do not predict subsequent systemic reactions, so routine dose adjustment based on a single local reaction is not recommended. Applying ice and taking an OTC antihistamine can reduce discomfort. Large local reactions — swelling larger than a golf ball — should be reported to your allergist.

Allergy shot vials contain allergen extracts — purified proteins derived from the specific allergens causing your symptoms: pollens, dust mite fecal particles and body parts, animal dander proteins, mold spores, or insect venom. These extracts are suspended in a solution containing glycerin (50%) or human serum albumin plus phenol as preservatives. Some formulations use aluminum hydroxide as an adjuvant to enhance immune response, particularly in depot formulations common in Europe. There are no corticosteroids, antihistamines, or biologics in standard SCIT vials. The extracts are FDA-standardized for 19 specific allergens, while others are prepared as non-standardized extracts in protein nitrogen units (PNU) or weight-by-volume concentrations.

The mandatory 30-minute waiting period after each allergy shot exists because approximately 85% of systemic allergic reactions — including anaphylaxis — occur within 30 minutes of the injection, according to surveillance data from Epstein et al. (Ann Allergy Asthma Immunol 2011). During this observation period, medical staff can immediately recognize and treat any systemic reaction with epinephrine and supportive care. Reactions occurring after 30 minutes (delayed reactions) are rare and less severe on average, though patients should still be aware of warning signs such as hives, throat tightening, or difficulty breathing for several hours after leaving the office. The observation requirement is a non-negotiable safety standard, not an option.

No — the initial rise in allergen-specific IgE that some patients experience in the first weeks of allergy shots is a normal and expected part of the immune retraining process, not a sign of worsening. This 'IgE paradox,' described by Gleich et al. (J Immunol 1982), reflects early immune activation as the body responds to the new allergen exposure. Over months to years of continued treatment, IgE levels gradually decline as IgG4 blocking antibodies rise and Treg-mediated suppression reduces IgE production. Some patients notice slightly more reactive allergy symptoms in the first weeks of treatment as a result; this typically resolves as the Treg response becomes established and IgG4 levels rise to protective concentrations.